Advisory Research’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Advisory Research’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-235,000	Closed	-$5.66M	–	515
2023 Q1	$5.66M	Sell	235,000 -53,707	-19%	-$674K	0.93%	27
2022 Q4	$3.05M	Buy	288,707 +53,707	+23%	+$433K	0.29%	57
2022 Q3	$1.06M	Hold	235,000	–	–	0.1%	157
2022 Q2	$940K	Hold	235,000	–	–	0.09%	162
2022 Q1	$1.72M	Hold	235,000	–	–	0.14%	118
2021 Q4	$1.32M	Sell	235,000 -2,500	-1%	-$15.9K	0.1%	172
2021 Q3	$1.52M	Hold	237,500	–	–	0.1%	158
2021 Q2	$2M	Hold	237,500	–	–	0.13%	137
2021 Q1	$2.49M	Buy	+237,500	New	+$3.34M	0.18%	114

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Advisory Research's PRVB Position: Q2 2023 in Review

Advisory Research sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 235,000 shares — an estimated $5.66M sold.

Advisory Research first reported a position in PRVB in Q1 2021 and held it in 9 quarters. The position peaked at $5.66M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Advisory Research reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Advisory Research sold 235,000 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $5.66M.
Advisory Research first reported a position in Provention Bio, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
Advisory Research's Provention Bio, Inc. Common Stock position peaked at $5.66M in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Advisory Research's 13F filing for Q2 2023, filed 14 Aug 2023.